address1,city,zip,country,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,executiveTeam,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,tradeable,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,quoteType,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,symbol,language,region,typeDisp,quoteSourceName,triggerable,customPriceAlertConfidence,fullExchangeName,averageDailyVolume3Month,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekChangePercent,earningsTimestampStart,earningsTimestampEnd,isEarningsDateEstimate,epsTrailingTwelveMonths,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeDataDelayedBy,cryptoTradeable,regularMarketChange,regularMarketDayRange,shortName,longName,hasPrePostMarketData,firstTradeDateMilliseconds,corporateActions,marketState,exchange,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,regularMarketChangePercent,regularMarketPrice,regularMarketTime,trailingPegRatio
Norra Vallgatan 72,Malmö,211 22,Sweden,https://pilapharma.com,Biotechnology,biotechnology,Biotechnology,Healthcare,healthcare,Healthcare,"Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.","[{'maxAge': 1, 'name': 'Ms. Dorte Xenia Gram', 'age': 55, 'title': 'Founder, Chairman & Chief Scientific Officer', 'yearBorn': 1969, 'fiscalYear': 2023, 'totalPay': 1588719, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gustav Hanghoj Gram', 'title': 'Chief Executive Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Hampus  Darrell', 'age': 51, 'title': 'Chief Financial Officer', 'yearBorn': 1973, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Miguel  Lecumberri', 'title': 'Head of Compliance & Legal Affairs', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Masoud  Alavi', 'title': 'Head of Corporate Visual Communication', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andy  Makin', 'title': 'Head of Toxicology', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Maura  McArdle', 'title': 'Head of BD & Quay Pharma', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mike  Frodsham', 'title': 'CTO of Quay Pharma', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Alison  Foster', 'title': 'Head of Pre-Clinical - Quay Pharma', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Simon  Hamilton', 'title': 'Head of Global Business Development - Almac', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]",1703980800,[],86400,4,3.325,3.75,3.555,3.92,3.325,3.75,3.555,3.92,0.0,0.606,155767,155767,44740,104297,104297,3.665,3.75,114347240,2.4,7.3,144.76369,3.0459924,3.7614481,0.0,0.0,SEK,False,65636224,0.0,11512268,30411500,0.3183,0.01798,30411500,0.194,19.381443,1735603200,1767139200,1735603200,-11241284,-0.39,83.096,-9.334,-0.44397992,0.10611236,EQUITY,3.76,none,4892994,0.18,-7031695,0,5.161,5.211,789889,0.031,-0.69053,-1.88568,789889,-4664471,-7822986,-0.854,1.0,0.0,-37.666203,SEK,PILA.ST,en-US,US,Equity,Delayed Quote,True,HIGH,Stockholm,44740,1.3599999,0.5666666,2.4 - 7.3,-3.5400002,-0.48493153,-44.39799,1709117940,1709117940,False,-0.39,0.7140076,0.23440887,-0.0014481544,-0.00038499918,15,0,False,0.43499994,3.555 - 3.92,PILA PHARMA AB,Pila Pharma AB (publ),False,1626332400000,[],PREPRE,STO,finmb_329992468,Europe/Stockholm,CEST,7200000,se_market,False,13.0827055,3.76,1752505798,
